HeartFlow

Bottom line

HeartFlow delivers non-invasive fractional flow reserve (FFR) and plaque quantification from standard coronary CT angiography (CCTA), eliminating the need for invasive catheterization in many patients. It holds FDA De Novo clearance, CE-IVDR certification, and reimbursement via CPT code 75577 as of January 2026. The evidence base is the strongest in the CCTA AI category, anchored by a 2026 meta-analysis confirming prognostic value for major adverse cardiovascular events.

Best fit: hospital cardiology departments and integrated delivery networks with established CCTA volume and interventional cardiology service lines. The enterprise per-study pricing model is reimbursable but lacks public transparency on implementation costs. HeartFlow filed for IPO in 2026, signaling vendor stability.

Skip if you lack in-house CCTA capability, operate outside cardiology subspecialty settings, or require named EHR integrations upfront. Ground-level clinician feedback is absent (zero Reddit mentions), which suggests either niche early adoption or limited workflow visibility outside interventional cardiology circles. Budget for discovering integration friction not documented in vendor materials.

Why we picked it

HeartFlow stands alone in the CCTA AI space for three reasons: the depth of its evidence base, the clarity of its reimbursement pathway, and its regulatory pedigree. A 2026 systematic review and meta-analysis published in Open Heart confirms that CT-derived fractional flow reserve (FFR-CT) has prognostic value for major adverse cardiovascular events in patients with suspected or known coronary artery disease. That evidence separates HeartFlow from AI tools with retrospective validation only.

The FDA De Novo clearance (the agency's pathway for novel moderate-risk devices with no predicate) signals rigorous clinical scrutiny. CE-IVDR certification extends that trust to European markets. More importantly, the January 2026 assignment of CPT code 75577 removes the reimbursement ambiguity that has stalled other CCTA AI tools. CMS now pays for HeartFlow studies, which directly addresses the adoption barrier for risk-averse health systems.

HeartFlow eliminates invasive coronary angiography for many patients by providing functional hemodynamic data (FFR) alongside anatomic plaque analysis, all from a non-invasive CCTA scan. Interventional cardiologists can stratify patients more precisely, reducing unnecessary catheterizations and their associated risks, costs, and patient anxiety. The IPO filing in 2026 suggests the vendor has revenue traction and institutional investor confidence.

We picked HeartFlow as the best reimbursable CCTA AI because it has solved the three adoption blockers simultaneously: clinical evidence, regulatory approval, and payment infrastructure. Competing tools have one or two of these elements, but not all three.

What it does well

HeartFlow takes standard CCTA DICOM images and generates two outputs: a coronary-specific fractional flow reserve value (FFR-CT) for each vessel segment, and a quantitative plaque burden analysis. The FFR-CT component is the clinical differentiator. Traditional CCTA visualizes stenosis anatomy but cannot determine whether a lesion is hemodynamically significant without invasive wire-based FFR measurement during catheterization. HeartFlow computes FFR non-invasively using computational fluid dynamics applied to the CCTA-derived 3D coronary anatomy.

A 2024 study in Radiology: Cardiothoracic Imaging validated HeartFlow's AI-enabled plaque quantification tool (AI-QCPA) against intravascular ultrasound (IVUS), the gold standard for plaque volume measurement. The study confirmed diagnostic performance within clinically acceptable margins, meaning the AI-derived plaque metrics can inform decision-making without requiring invasive IVUS. This dual capability (functional FFR plus structural plaque data) allows cardiologists to answer both whether to intervene and where to intervene from a single CCTA study.

The reimbursement pathway via CPT 75577 is operationally straightforward: the ordering clinician submits the CCTA images to HeartFlow, receives a report with FFR-CT values and plaque maps, and bills the CPT code. CMS reimbursement removes the patient cost barrier that plagued earlier AI diagnostics. Hospitals can adopt HeartFlow without carving out separate budget lines, because payer coverage exists.

Clinically, HeartFlow reduces the rate of invasive coronary angiography by identifying patients whose stenoses are anatomically visible on CCTA but functionally non-significant by FFR-CT criteria. This avoids unnecessary catheterizations, which carry procedural risk (bleeding, vascular injury, contrast nephropathy) and patient anxiety. For stable chest pain pathways, HeartFlow enables a non-invasive rule-out strategy that aligns with ACC/AHA guidelines favoring functional testing before invasive procedures.

Where it falls short

Ground-level clinician feedback is absent. Zero mentions surfaced in Reddit's medical communities (r/medicine, r/Radiology, r/cardiology), which suggests either that HeartFlow adoption is confined to interventional cardiology specialists who do not frequent those forums, or that market penetration remains early-stage despite the 2026 reimbursement milestone. This absence is a red flag for prospective buyers: you cannot calibrate workflow fit, training friction, or report usability from peer accounts.

Pricing transparency is poor. The vendor describes an enterprise per-study model but does not disclose per-study rates, volume thresholds for discounts, or implementation fees. Health systems accustomed to transparent SaaS pricing will find this opaque. The CPT 75577 reimbursement covers the clinical service but does not clarify whether hospitals net-positive, break-even, or subsidize each study after accounting for HeartFlow's fee. Contract terms (annual minimums, opt-out provisions, price escalation clauses) are not public.

EHR integration depth is undocumented in available materials. The vendor does not name Epic, Cerner, or Meditech partnerships, nor does it specify whether HeartFlow writes results back into the EHR automatically or requires manual entry. For CMIOs evaluating AI tools, EHR write-back is a non-negotiable workflow requirement. If HeartFlow operates as a standalone web portal with PDF reports, that introduces transcription errors and clinician friction.

Training requirements are not quantified. The FFR-CT reports include color-coded coronary trees and numeric FFR values, but interpreting these outputs requires familiarity with hemodynamic thresholds (FFR <0.80 indicates ischemia). Cardiologists trained in invasive FFR will adapt quickly, but general radiologists reading CCTA may need structured training. The vendor does not publish training hours per clinician or proficiency timelines, leaving deployment planning opaque.

Deployment realities

HeartFlow requires an existing CCTA program as baseline infrastructure. Hospitals without CT scanners capable of cardiac gating, contrast protocols, and submillimeter spatial resolution cannot adopt HeartFlow. This restricts the addressable market to academic medical centers, large community hospitals with cardiology service lines, and integrated delivery networks. Solo cardiology practices or small hospitals without in-house advanced imaging are excluded unless they partner with imaging centers.

Workflow coordination spans radiology and cardiology. The CCTA study is typically ordered by cardiology but performed and initially read by radiology. HeartFlow analysis requires exporting DICOM images to the vendor's cloud platform, which introduces a handoff step. Turnaround time for HeartFlow reports is not specified in public materials, but prior coverage suggests 24-48 hours. This latency means HeartFlow is unsuitable for acute chest pain pathways (where troponin and ECG drive immediate decisions) and best suited for stable outpatient evaluation.

IT teams will need to establish secure DICOM transmission to HeartFlow's cloud environment, ensure HIPAA-compliant data handling agreements are in place, and determine how reports return to the EHR. If HeartFlow lacks a native HL7 or FHIR integration, IT must configure manual report upload workflows or accept clinician portal-switching. Change management requires buy-in from interventional cardiology (who will act on FFR-CT results), radiology (who will export images), and cardiology administration (who will monitor utilization and reimbursement). Expect 3-6 months from contract signature to go-live in a typical 200-bed hospital.

Pricing realities

HeartFlow operates on an enterprise per-study fee structure. The vendor does not publish list prices, but the CPT 75577 reimbursement (assigned January 2026) signals that CMS views the service as a separately billable procedure rather than bundled into the base CCTA read. Hospital finance teams should model net reimbursement by subtracting HeartFlow's per-study fee from the CPT 75577 payment, adjusted for payer mix (Medicare, Medicaid, commercial). If the HeartFlow fee exceeds the reimbursement, the hospital subsidizes each study.

Hidden costs include implementation fees (DICOM integration, training), ongoing support charges (not specified), and potential volume commitments in enterprise contracts. Health systems with low CCTA volume (<100 studies/year) may face minimum purchase requirements that push per-study costs above reimbursement thresholds. High-volume centers (>500 studies/year) likely negotiate volume discounts, but these terms are not transparent. Budget for contractual lock-in periods (annual or multi-year) with early termination penalties.

ROI hinges on avoided invasive catheterizations. If HeartFlow prevents one unnecessary diagnostic catheterization per 10 studies, and each cath costs the system $3,000-$5,000 in direct costs (facility, staff, contrast, disposables), the cost avoidance can justify HeartFlow fees even at $500-$1,000 per study. However, this math assumes accurate FFR-CT-guided decision-making and requires tracking downstream cath lab utilization post-HeartFlow adoption. Hospitals without robust analytics infrastructure will struggle to prove ROI internally, which complicates contract renewal justifications.

Compliance + integration depth

HeartFlow holds FDA De Novo clearance (Class II device) and CE-IVDR certification, which are the two gold-standard regulatory approvals for AI-enabled diagnostics in the US and Europe. The De Novo pathway indicates the FDA found no substantial equivalence to predicate devices but cleared HeartFlow based on clinical performance data, which is stronger than 510(k) clearance. CE-IVDR (the updated In Vitro Diagnostic Regulation) imposes stricter post-market surveillance and clinical evidence requirements than the prior CE-IVD directive, so HeartFlow's compliance signals ongoing vendor investment in regulatory maintenance.

HIPAA compliance is presumed but not explicitly documented in available materials. Because HeartFlow processes CCTA DICOM images in a cloud environment, the vendor must function as a Business Associate under HIPAA, with appropriate safeguards for data encryption, access logging, and breach notification. Prospective buyers should request SOC 2 Type II audit reports and BAA templates during procurement. HITRUST certification (a healthcare-specific security framework) is not mentioned and may be absent, which could be a blocker for health systems with strict vendor security tiers.

EHR integration specifics are not disclosed. The vendor does not name partnerships with Epic, Cerner (Oracle Health), Meditech, or Allscripts. If HeartFlow operates as a standalone web portal, results may return as PDF attachments rather than discrete data fields that populate the EHR's cardiology flowsheets. This limits downstream analytics (tracking FFR-CT values across patient populations) and forces clinicians to context-switch between systems. For CMIOs, the absence of named EHR integrations is a procurement red flag. Specialty-society endorsements (American College of Cardiology, Society of Cardiovascular Computed Tomography) are not mentioned in available materials, though the evidence base would support such endorsements if pursued.

Vendor stability + roadmap

HeartFlow Inc is a US-based company that filed for an initial public offering in 2026, indicating revenue scale sufficient to attract institutional investors and meet SEC disclosure thresholds. IPO filings require audited financials, which means the vendor has survived due diligence from underwriters and operates under heightened governance standards. This is a strong vendor-stability signal compared to early-stage startups without public financial accountability.

Acquisition history and leadership details are not available in source materials, but the IPO trajectory suggests the company has maintained independence rather than being absorbed by a larger imaging or EHR vendor. Customer references are not named in public materials, which is unusual for a tool with FDA clearance and reimbursement. Prospective buyers should request reference calls with similar-sized health systems during procurement to assess implementation timelines and satisfaction.

Roadmap is not publicly disclosed, but industry trends in AI cardiology suggest likely expansion into plaque phenotyping (classifying calcified vs non-calcified vs mixed plaque), longitudinal plaque progression tracking, and integration with coronary artery calcium (CAC) scoring for primary prevention pathways. The vendor's participation in clinical trials (evidenced by the PubMed citations) indicates ongoing investment in evidence generation, which is necessary to maintain reimbursement and expand indications.

How it compares

Cleerly is HeartFlow's closest competitor in the CCTA AI space. Cleerly focuses on comprehensive plaque quantification and phenotyping (calcified, non-calcified, low-attenuation) but does not offer FFR-CT. Cleerly wins when the clinical question is plaque burden for risk stratification (primary prevention, statin titration), while HeartFlow wins when the question is whether an anatomic stenosis is hemodynamically significant (guiding revascularization decisions). Cleerly does not yet have a dedicated CPT code for its plaque analysis as of early 2026, which makes reimbursement less certain.

Aidoc is a general radiology AI triage platform that flags critical findings (pulmonary embolism, intracranial hemorrhage, cervical spine fractures) but is not CCTA-specific. Aidoc operates earlier in the radiology workflow (prioritizing worklist order) rather than providing diagnostic outputs like FFR-CT. Health systems may deploy both Aidoc for general triage and HeartFlow for CCTA analysis, as they serve different workflow stages.

vRad (Virtual Radiologic) offers teleradiology services with AI-assisted reads but is a service model (outsourced radiologist interpretations) rather than a diagnostic tool. vRad may incorporate AI for quality control or efficiency but does not provide standalone FFR-CT reports that ordering clinicians can act on independently. Health systems using vRad for after-hours radiology coverage would still need HeartFlow separately if they want FFR-CT capability.

HeartFlow's competitive advantage is the combination of strong evidence (meta-analysis-backed prognostic value), regulatory clarity (FDA De Novo), and reimbursement infrastructure (CPT 75577). Cleerly may close the reimbursement gap if it secures a CPT code for plaque quantification, but as of early 2026, HeartFlow is the only CCTA AI with all three elements aligned. For hospitals prioritizing coronary artery disease functional assessment, HeartFlow is the category leader. For primary prevention plaque tracking, Cleerly is the better fit.

What clinicians say

Zero mentions surfaced in Reddit's medical communities (r/medicine, r/Radiology, r/cardiology) as of the review date. This absence is striking given that Reddit hosts active discussions of other AI radiology tools (Aidoc, Annalise.ai) and cardiac imaging workflows. The lack of ground-level clinician feedback suggests three possibilities: HeartFlow adoption is concentrated in interventional cardiology subspecialists who do not frequent general medical forums; the tool is too new (despite FDA clearance predating 2026) to have reached critical mass; or workflow integration is seamless enough that clinicians do not surface complaints or praise.

Prospective buyers cannot assess clinician satisfaction, training friction points, report usability, or EHR integration pain from peer accounts. This is a deployment risk. Health systems should request HeartFlow to provide direct contact with peer institutions (similar size, similar EHR, similar CCTA volume) during procurement. Early adopters should budget for discovering workflow issues that would normally surface in Reddit threads or professional society forums but are currently undocumented.

The absence of feedback is not itself disqualifying, especially given the strength of the evidence base and regulatory approvals. However, it shifts risk to the buyer. Without peer validation of workflow fit, each new HeartFlow customer is effectively piloting the integration independently.

What the literature says

A 2026 systematic review and meta-analysis in Open Heart assessed the prognostic value of FFR-CT for major adverse cardiovascular events (MACE) in patients with suspected or known coronary artery disease. The study pooled results across multiple trials and confirmed that FFR-CT stratifies risk effectively, with patients having FFR-CT values below 0.80 showing higher MACE rates than those above the threshold. This supports using HeartFlow to guide decisions on invasive angiography and revascularization, rather than relying on anatomic stenosis severity alone.

A 2024 observational study in Radiology: Cardiothoracic Imaging validated HeartFlow's AI-enabled plaque quantification tool (AI-QCPA) against intravascular ultrasound (IVUS) in a single-center retrospective cohort. The study found that AI-QCPA measured plaque volume with diagnostic performance comparable to IVUS, which is the invasive gold standard. This means clinicians can trust the AI-derived plaque burden metrics for risk stratification without requiring IVUS, which is resource-intensive and typically reserved for complex lesions during catheterization.

Three reviews published in 2025 (Discoveries, International Journal of Cardiovascular Imaging, Cureus) position HeartFlow within the broader landscape of AI in cardiovascular imaging. All three cite HeartFlow as a leading example of AI-enabled functional assessment, noting its FDA clearance and clinical adoption. The reviews do not present original data but synthesize existing evidence, reinforcing that HeartFlow has achieved the level of visibility in academic cardiology literature that typically precedes widespread adoption. The evidence base is the strongest in the CCTA AI category, which justifies our editorial pick.

Who it's for

HeartFlow is built for hospital cardiology departments and integrated delivery networks with established CCTA programs and interventional cardiology service lines. Best fit: academic medical centers performing >500 CCTA studies annually; large community hospitals with on-site cath labs; IDNs with centralized cardiac imaging and distributed cardiology clinics. The tool serves interventional cardiologists deciding whether to proceed with invasive angiography, non-invasive cardiologists stratifying stable chest pain, and radiologists seeking to add functional data to anatomic CCTA reads.

Skip HeartFlow if you lack in-house CCTA capability. Solo primary care practices, small rural hospitals without advanced imaging, and outpatient cardiology groups relying on external imaging centers cannot operationalize HeartFlow without partnerships. Also skip if your patient population skews toward acute chest pain presentations (emergency department, observation unit), where troponin and ECG drive immediate triage and the 24-48 hour HeartFlow turnaround is too slow. HeartFlow is for stable outpatient evaluation, not acute rule-out.

CMIOs evaluating HeartFlow should have cath lab utilization data and CCTA volume metrics ready. If your system performs fewer than 100 CCTA studies annually, HeartFlow's enterprise per-study model may not achieve ROI given likely volume minimums. If your interventional cardiologists already use invasive FFR wires routinely, the value proposition is weaker (though non-invasive FFR-CT still avoids catheterization for patients who turn out to be functionally non-significant). The tool fits best in systems where CCTA is underutilized because anatomic reads alone do not provide enough confidence to defer catheterization.

The verdict

HeartFlow is the most evidence-backed, reimbursable CCTA AI for coronary artery disease functional assessment. The combination of FDA De Novo clearance, CE-IVDR certification, CPT 75577 reimbursement, and meta-analysis validation makes it the category leader for health systems seeking to reduce invasive catheterizations while maintaining diagnostic accuracy. The IPO filing signals vendor stability. The clinical use case (non-invasive FFR to guide revascularization decisions) is well-established in ACC/AHA guidelines and aligns with payer priorities for cost-effective cardiology pathways.

Buy HeartFlow if you have established CCTA volume (>200 studies/year), on-site interventional cardiology, and a strategic goal to reduce unnecessary diagnostic catheterizations. Expect ROI via cost avoidance (fewer cath lab procedures, shorter hospital stays, reduced contrast nephropathy events). Budget 3-6 months for deployment and plan for cross-departmental workflow coordination between radiology, cardiology, and IT. Request reference calls with peer institutions during procurement to validate workflow fit, because ground-level clinician feedback is absent in public forums.

Hesitate if EHR integration is a hard requirement and you need named Epic or Cerner partnerships upfront. The vendor does not disclose integration depth in available materials, which means you may face manual report handling workflows. Also hesitate if pricing transparency matters to your finance team; the enterprise per-study model lacks public rate cards and may include volume minimums or hidden implementation fees. Skip HeartFlow entirely if you lack CCTA baseline infrastructure, operate outside cardiology subspecialty settings, or serve primarily acute chest pain populations. For primary prevention plaque tracking (rather than revascularization decisions), Cleerly is a better fit. For general radiology triage, Aidoc is more appropriate. HeartFlow wins when the clinical question is functional significance of coronary stenoses in stable patients.